Investment
Features
FeesSafety
Academy
More
Pluang+

Virtus Diversified Income & Convertible Fund shows strong returns but caution advised due to tech exposure and valuation risks.

Market News
19 Jul 2026
Seeking Alpha
View Source
Neutral
pluang ai news

The Virtus Diversified Income & Convertible Fund (ACV) has delivered strong total returns recently, helped by a narrowing discount to its net asset value and solid performance in the technology sector. The fund currently trades at a small discount of -1.31% and offers a yield of 7.94%. However, its heavy exposure to tech stocks and convertible securities raises concerns amid high equity valuations. While the fund's stable distributions are attractive, the payout relies more on capital gains than net investment income, making its sustainability sensitive to market fluctuations. The analyst remains neutral on ACV, preferring to wait for a wider discount or market correction before investing due to current valuations and sector concentration risks.

More News

Sampo Oyj repurchased 968,363 A-shares in week 29 at an average price of €9.53 each.

Sampo Oyj repurchased 968,363 A-shares in week 29 at an average price of €9.53 each.

During week 29 of 2026 (July 13-17), Sampo Oyj bought back 968,363 of its own A-shares across multiple markets at a weighted average price of €9.53 per share. This buyback is part of a program authorized by the company's annual general meeting in Apr...

Company Fundamentals
Neutral
56 minutes ago
Royal Unibrew increases share buy-back program to DKK 700m, repurchasing 3.2% of shares by mid-July 2026

Royal Unibrew increases share buy-back program to DKK 700m, repurchasing 3.2% of shares by mid-July 2026

Royal Unibrew initiated a share buy-back program in February 2026, which was increased from DKK 400 million to DKK 700 million in April 2026. The program, running until August 14, 2026, has seen the company repurchase a total of 1,335,000 shares by m...

Company Fundamentals
Bullish
1 hour ago
Fangzhou launches world's first once-weekly basal insulin/GLP-1 therapy in China to improve diabetes care.

Fangzhou launches world's first once-weekly basal insulin/GLP-1 therapy in China to improve diabetes care.

Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...

Others
Bullish
4 hours ago
Zcash completes major software upgrade, boosting security and user confidence amid steady network use

Zcash completes major software upgrade, boosting security and user confidence amid steady network use

Zcash has finished transitioning from its original software to a new Rust-based system, enhancing network maintainability and security. Despite a recent vulnerability in its privacy pools, user trust remains strong, with private transactions and trad...

Protocol Fundamentals
Bullish
4 hours ago
Lockheed Martin launches PAC-3 ACE interceptor costing less than half of PAC-3 MSE.

Lockheed Martin launches PAC-3 ACE interceptor costing less than half of PAC-3 MSE.

Lockheed Martin introduced the PAC-3 ACE, a low-cost missile interceptor designed to counter various air and missile threats at less than half the unit cost of the PAC-3 MSE. The PAC-3 ACE integrates with the Patriot system and the Integrated Battle ...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App